What are the common brands of Teriparatide (Teriparatide) available in India?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Common Teriparatide Brands Available in India

In India, teriparatide is available under various brand names, though specific Indian brand information is limited in the provided evidence.

Teriparatide is an important medication for treating severe osteoporosis, particularly in patients at very high risk of fractures. Here's what we know about teriparatide brands and their use:

General Information on Teriparatide

  • Teriparatide is a recombinant parathyroid hormone (PTH 1-34) that acts as an anabolic (bone-forming) agent, unlike bisphosphonates which are antiresorptive 1
  • It is typically administered as a 20 μg daily subcutaneous injection for a treatment period of up to 2 years 2, 1
  • Internationally, teriparatide is marketed under the brand name Forteo/Forsteo by Eli Lilly 1, 3

Indications for Teriparatide Use

  • Teriparatide is suggested for females with primary osteoporosis at very high risk of fracture (conditional recommendation; low-certainty evidence) 2
  • It is typically used as a third-line agent after bisphosphonates (first-line) and denosumab (second-line) 2
  • High-risk patients include those with:
    • Older age
    • Recent fracture (within past 12 months)
    • History of multiple clinical osteoporotic fractures
    • Multiple risk factors for fracture
    • Failure of other available osteoporosis therapies 2

Efficacy of Teriparatide

  • Teriparatide reduces the risk of vertebral fractures (high certainty) and may reduce clinical vertebral fractures (low certainty) compared to placebo 2
  • It has been shown to increase bone mineral density (BMD) in both men and women with osteoporosis 1, 4
  • Compared to bisphosphonates, teriparatide probably reduces risk for radiographic vertebral fractures (moderate certainty) and may reduce risk for any clinical fracture (low certainty) 2

Important Considerations and Limitations

  • Teriparatide should be followed by an antiresorptive agent after completion to prevent rapid bone loss 2
  • It is contraindicated in patients with:
    • Paget's disease of bone
    • Open epiphyses
    • Prior radiation therapy involving the skeleton
    • Bone metastases or history of malignancy prone to metastasize to bone 2
  • Common side effects include nausea, dizziness, vomiting, headache, palpitations, and leg cramps 2
  • Teriparatide may increase the risk for withdrawal due to adverse events 2
  • Due to high cost, teriparatide is typically reserved for patients with severe osteoporosis who have failed or cannot tolerate other therapies 1, 5

Administration

  • Teriparatide is administered via a delivery device for subcutaneous injection 3
  • Patient studies have shown high satisfaction with newer delivery devices, with 99.5% of patients finding them easy to use 3

While the evidence provided does not specifically list Indian brand names for teriparatide, the medication is available in India and would likely be prescribed according to the same clinical guidelines as outlined above, with consideration for local regulatory approvals and availability.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Patient experience with a new teriparatide delivery device.

Current medical research and opinion, 2009

Research

Teriparatide: a review.

Clinical therapeutics, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.